Core Insights - Dr. Park CDMO has selected Thermo Fisher Scientific to equip its new viral vector manufacturing facility, aiming to enhance large-scale production and global access to cell and gene therapies [1][4] Group 1: Company Overview - Dr. Park specializes in Adeno-associated virus-based (AAV-based) viral vector production, currently operating at a capacity of 5,000 L per batch and producing up to 40 clinical-grade batches annually [2] - The new Phase 1 facility was inaugurated on August 5, 2025, with plans to achieve cGMP certification in 2026 and to expand capacity to 10,000 L per batch in the future [2] Group 2: Technological Integration - The facility will utilize several advanced solutions from Thermo Fisher, including the HyPerforma™ 1,000 L Single-Use Bioreactor and DynaSpin™ Single-Use Centrifuge, aimed at streamlining production processes and enhancing efficiency [3] - These technologies are designed to improve process control and automation, thereby supporting rapid scale-up from clinical to commercial production while maintaining high standards of quality and regulatory compliance [3] Group 3: Strategic Collaboration - The collaboration between Dr. Park CDMO and Thermo Fisher is seen as crucial for advancing viral vector manufacturing in South Korea, reflecting the growing importance of robust manufacturing infrastructure for cell and gene therapies [4][5] - Both companies emphasize the need for collaboration to accelerate the development and delivery of therapies to patients, addressing the rising global demand for gene therapy [5]